Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

Wuhan University

Status and phase: Unknown; Phase 4

Conditions: Atrial Fibrillation

Treatments: Drug: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists; Procedure: catheter ablation

Study type: Interventional

Funder types: Other

Identifiers

NCT01341353

CAPA001

Details and patient eligibility

About

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

Enrollment: 1,800 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial

Exclusion criteria

• 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,800 participants in 2 patient groups

Antiarrythmic Drugs

Active Comparator group

Treatment:

Drug: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists

ablation

Experimental group

Treatment:

Procedure: catheter ablation